Literature DB >> 30887577

Importance of out-of-pocket costs for adult patients with atopic dermatitis in France.

R Launois1, K Ezzedine2,3, E Cabout1, Z Reguai4, S Merrhand5, S Heas6, J Seneschal7, L Misery8,9, C Taieb10,11.   

Abstract

BACKGROUND: Currently, few studies investigated the economic burden of atopic dermatitis (AD) in adult patients and specifically the estimation of out-of-pocket costs. Patients with skin disorders primarily use comfort care to ease dryness, itch or pain, and the costs of comfort care are not subject to any reimbursement from mandatory or complementary insurance.
OBJECTIVE: The purpose of this study was to measure the medical and non-medical expenses paid by the patient.
METHODS: Eczema Cohort Longitudinal Adults was a non-interventional study that aimed to assess the burden of AD in terms of quality of life and financial consequences. A self-assessment questionnaire was distributed to adult patients who were cared in four French hospitals. Patients were asked to list the resources consumed for the treatment of AD during the last 12 months and to estimate the corresponding amount of money they had to pay out of their own pockets. The severity of AD was subjected to a stratification based on the PO-SCORAD score.
RESULTS: A total of 1024 patients answered the questionnaire: 31.9% with severe AD, 40.4% with moderate AD and 27.6% with mild AD. The mean annual out-of-pocket cost was €462.1 for severe AD and €247.4 for moderate AD. Emollients were the most commonly used product: 74.4% for an average out-of-pocket cost of €151.4. The out-of-pocket costs increased significantly with the severity: 27% of patients with severe AD declared having bought specially textured clothes, while 19% of patients with moderate AD reported the same. The corresponding mean out-of-pocket costs were €162 and €91, respectively.
CONCLUSION: The amount of out-of-pocket costs for patients with AD for essential medical and non-medical expenses is relatively high, compared to the average out-of-pocket cost for French households. Integration of these essential resources into the list of reimbursed products and services appears necessary for a better coverage of AD.
© 2019 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30887577     DOI: 10.1111/jdv.15581

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

1.  Prescription Behaviour and Barriers to Prescription of Biologicals for Treatment of Chronic Inflammatory Skin Diseases in Dermatological Practice in Two German Federal States.

Authors:  Daniela Weiss; Imke Nordhorn; Linda Tizek; Thomas Werfel; Alexander Zink; Tilo Biedermann; Stephan Traidl; Maximilian C Schielein
Journal:  Acta Derm Venereol       Date:  2021-09-28       Impact factor: 3.875

Review 2.  Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review.

Authors:  Ahmad N Fasseeh; Baher Elezbawy; Nada Korra; Mohamed Tannira; Hala Dalle; Sandrine Aderian; Sherif Abaza; Zoltán Kaló
Journal:  Dermatol Ther (Heidelb)       Date:  2022-10-05

Review 3.  Current Perspectives on the Systemic Management of Atopic Dermatitis.

Authors:  Danielle R Davari; Elizabeth L Nieman; Diana B McShane; Dean S Morrell
Journal:  J Asthma Allergy       Date:  2021-06-01

4.  Cost Effectiveness of Emollients in the Prevention of Relapses in Atopic Dermatitis.

Authors:  Elise Cabout; Sebastien Eymere; Robert Launois; Flavia Aslanian; Charles Taïeb; Sophie Seité
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-12-21

5.  Cost-effectiveness of Emollients in the Prevention of Relapse among French Patients with Atopic Dermatitis.

Authors:  Elise Cabout; Sébastien Eymere; Robert Launois; Sophie Séité; Véronique Delvigne; Charles Taïeb; Ziad Reguai
Journal:  Acta Derm Venereol       Date:  2021-07-30       Impact factor: 3.875

6.  Financial Burden of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the United States.

Authors:  Wendy Smith Begolka; Raj Chovatiya; Isabelle J Thibau; Jonathan I Silverberg
Journal:  Dermatitis       Date:  2021-10-01       Impact factor: 4.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.